On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

published:28 May 2018

views:849

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affect those changes, which can lead to dementia. She says imaging can provide a window into brain changes, decades before someone begins to show clinical symptoms of Alzheimer's or dementia.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

published:02 Nov 2017

views:1339

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

published:23 Apr 2014

views:61561

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

published:26 Sep 2018

views:813

UCLA psychiatrist Gary Small, MD, discusses early-onset Alzheimer's disease, its similarities and differences from late-onset disease, and what patients and families at any age need to know.

published:03 Oct 2016

views:5117

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are formed in a brain without exercise."
Preliminary research is showing much the same in humans; that staying physically fit may slow brain shrinkage.
Aerobic exercise, walking or anything that gets the heart pumping increases blood volume and promotes new cell growth. It's that cell growth that's linked to improved memory.
"So if you want to stay at home longer then physical exercise slows the memory loss by generating new nerve cells making the cells that are there healthier," says Dr. Raab.
And it's not just the body that could use a workout.
"By adding the brain exercises, especially the processing speed and reasoning, and retraining yourself and how to use your brain more efficiently through the memory techniques you're able to slow down the impact on your function and your ability to do things in life," says Dr. Raab.
It's well known that staying fit helps older adults without dementia offset cognitive decline. The hope is that Alzheimer's sufferers can put physical activity to work for them too.
View More HealthMatters video segments at leememorial.org/healthmatters/
Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries.
Visit leememorial.org/caring

published:25 Jul 2011

views:14792

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

Mayo Clinic

Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota. It is the first and largest integrated nonprofit medical group practice in the world, employing more than 3,800 physicians and scientists and 50,900 allied health staff. The practice specializes in treating difficult cases through tertiary care. It spends over $500 million a year on research.

Dr. William Worrall Mayo settled his family in Rochester in 1864 and opened a medical practice that evolved under his sons into Mayo Clinic. Mayo Clinic is widely regarded as one of the world's greatest hospitals and ranked No. 1 on the 2014–2015 U.S. News & World Report List of "Best Hospitals", maintaining a position near the top for more than 20 years. It has been on the list of America's "100 Best Companies to Work For" published by Fortune magazine for eight consecutive years. It continued to achieve this ranking through 2015.

In addition to their flagship hospital in Rochester, the Mayo Clinic has major campuses in Arizona and Florida. The Mayo Clinic Health System also operates affiliated facilities throughout Minnesota, Wisconsin, and Iowa.

Alzheimer's disease

Alzheimer's disease (AD), also known as Alzheimer disease, or just Alzheimer's, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.

The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis.Mental and physical exercise, and avoiding obesity may decrease the risk of AD. There are no medications or supplements that decrease risk.

Phrase

In everyday speech, a phrase may be any group of words, often carrying a special idiomatic meaning; in this sense it is roughly synonymous with expression. In linguistic analysis, a phrase is a group of words (or possibly a single word) that functions as a constituent in the syntax of a sentence—a single unit within a grammatical hierarchy. A phrase appears within a clause, although it is also possible for a phrase to be a clause or to contain a clause within it.

In grammatical analysis, particularly in theories of syntax, a phrase is any group of words, or sometimes a single word, which plays a particular role within the grammatical structure of a sentence. It does not have to have any special meaning or significance, or even exist anywhere outside of the sentence being analyzed, but it must function there as a complete grammatical unit. For example, in the sentence Yesterday I saw an orange bird with a white neck, the words an orange bird with a white neck form what is called a noun phrase, or a determiner phrase in some theories, which functions as the object of the sentence.

Geography

Mount Sinai is a 2,285-metre (7,497ft) moderately high mountain near the city of Saint Catherine in the Sinai region. It is next to Mount Catherine (at 2,629m or 8,625ft, the highest peak in Egypt). It is surrounded on all sides by higher peaks of the mountain range.

Geology

Mount Sinai's rocks were formed in the late stage of the Arabian-Nubian Shield's (ANS) evolution. Mount Sinai displays a ring complex that consists of alkaline granites intruded into diverse rock types, including volcanics. The granites range in composition from syenogranite to alkali feldspar granite. The volcanic rocks are alkaline to peralkaline and they are represented by subaerial flows and eruptions and subvolcanicporphyry. Generally, the nature of the exposed rocks in Mount Sinai indicates that they originated from differing depths.

Hebrew Bible texts describe the theophany at Mount Sinai in terms which a minority of scholars, following Charles Beke (1873), have suggested may literally describe the mountain as a volcano and have led to a search for alternative locations.

Etymology

According to some biblical scholars, Horeb is thought to mean "glowing/heat", which seems to be a reference to the sun, while Sinai may have derived from the name of Sin, the Sumerian deity of the moon, and thus Sinai and Horeb would be the mountains of the moon and sun, respectively.

Advances in Alzheimer's disease Research

18:29

Redefining Alzheimer's Disease: Mayo Clinic Radio

Redefining Alzheimer's Disease: Mayo Clinic Radio

Redefining Alzheimer's Disease: Mayo Clinic Radio

On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

1:30

Alzheimer's disease drug shows early promise

Alzheimer's disease drug shows early promise

Alzheimer's disease drug shows early promise

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

Women’s Wellness: Hormone therapy and Alzheimer’s disease

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affect those changes, which can lead to dementia. She says imaging can provide a window into brain changes, decades before someone begins to show clinical symptoms of Alzheimer's or dementia.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

7:53

TDP43 and Alzheimer's Study

TDP43 and Alzheimer's Study

TDP43 and Alzheimer's Study

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

2:18

Using Biomarkers to Predict and Prevent Alzheimer's Disease

Using Biomarkers to Predict and Prevent Alzheimer's Disease

Using Biomarkers to Predict and Prevent Alzheimer's Disease

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

UCLA psychiatrist Gary Small, MD, discusses early-onset Alzheimer's disease, its similarities and differences from late-onset disease, and what patients and families at any age need to know.

1:54

Exercise in Early Stage Alzheimer's

Exercise in Early Stage Alzheimer's

Exercise in Early Stage Alzheimer's

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are formed in a brain without exercise."
Preliminary research is showing much the same in humans; that staying physically fit may slow brain shrinkage.
Aerobic exercise, walking or anything that gets the heart pumping increases blood volume and promotes new cell growth. It's that cell growth that's linked to improved memory.
"So if you want to stay at home longer then physical exercise slows the memory loss by generating new nerve cells making the cells that are there healthier," says Dr. Raab.
And it's not just the body that could use a workout.
"By adding the brain exercises, especially the processing speed and reasoning, and retraining yourself and how to use your brain more efficiently through the memory techniques you're able to slow down the impact on your function and your ability to do things in life," says Dr. Raab.
It's well known that staying fit helps older adults without dementia offset cognitive decline. The hope is that Alzheimer's sufferers can put physical activity to work for them too.
View More HealthMatters video segments at leememorial.org/healthmatters/
Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries.
Visit leememorial.org/caring

2:22

New Alzheimer's Research

New Alzheimer's Research

New Alzheimer's Research

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

2:45

Dr. Ronald Petersen discusses Alzheimer's research

Dr. Ronald Petersen discusses Alzheimer's research

Dr. Ronald Petersen discusses Alzheimer's research

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease had failed to show significant benefit to patients.
The trial used Eli Lilly’s drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of those with Alzheimer’s. The destruction of these plaques, which are a key player in the disease, had the potential to provide stabilization for Alzheimer’s patients. This goal, however, was not reached in the phase III clinical trial.

0:54

Alzheimer's disease drug fails in trial

Alzheimer's disease drug fails in trial

Alzheimer's disease drug fails in trial

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually no chance of finding a positive clinical effect.” The trial, called the EPOCH study, tested the efficacy and safety of the drug when taken orally in people with mild-to-moderate Alzheimer's disease. While this particular study was stopped, the president of Merck Research Laboratories, Dr. Roger M. Perlmutter, says in a news release that they will continue to study the drug in people with less advanced disease.
Mayo Clinic neurologist Dr. David Knopman says that while the news about this medication is disappointing, he remains optimistic about Alzheimer's Disease research. "We have to keep working towards therapies that are effective. As we become more knowledgeable about the disease, I think we will eventually achieve success."
Verubecestat is a base-inhibitor that breaks down a certain protein. The process then helps prevent the overproduction of amyloid protein, which many believe to be involved in causing Alzheimer's disease.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

Advances in Alzheimer's disease Research

published: 23 Oct 2017

Redefining Alzheimer's Disease: Mayo Clinic Radio

On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

published: 28 May 2018

Alzheimer's disease drug shows early promise

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

Women’s Wellness: Hormone therapy and Alzheimer’s disease

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affe...

published: 02 Nov 2017

TDP43 and Alzheimer's Study

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

published: 23 Apr 2014

Using Biomarkers to Predict and Prevent Alzheimer's Disease

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

UCLA psychiatrist Gary Small, MD, discusses early-onset Alzheimer's disease, its similarities and differences from late-onset disease, and what patients and families at any age need to know.

published: 03 Oct 2016

Exercise in Early Stage Alzheimer's

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are for...

published: 25 Jul 2011

New Alzheimer's Research

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

published: 31 Mar 2010

Dr. Ronald Petersen discusses Alzheimer's research

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease had failed to show significant benefit to patients.
The trial used Eli Lilly’s drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of those with Alzheimer’s. The destruction of these plaques, which are a key player in the disease, had the potential to provide stabilization for Alzheimer’s patients. This goal, however, was not reached in the phase III clinical trial.

published: 01 Dec 2016

Alzheimer's disease drug fails in trial

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually no chance of finding a positive clinical effect.” The trial, called the EPOCH study, tested the efficacy and safety of the drug when taken orally in people with mild-to-moderate Alzheimer's disease. While this particular study was stopped, the president of Merck Research Laboratories, Dr. Roger M. Perlmutter, says in a news release that they will continue to study the drug in people with less advanced disease.
Mayo Clinic neurologist Dr. David Knopman says that while the news about this medication is disappointing, he remains optimistic about Alzheimer's Disease research. "We have to keep working towards therapies that are effective...

On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

Alzheimer's disease drug shows early promise

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And ...

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

Women’s Wellness: Hormone therapy and Alzheimer’s disease

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulat...

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affect those changes, which can lead to dementia. She says imaging can provide a window into brain changes, decades before someone begins to show clinical symptoms of Alzheimer's or dementia.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affect those changes, which can lead to dementia. She says imaging can provide a window into brain changes, decades before someone begins to show clinical symptoms of Alzheimer's or dementia.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

Exercise in Early Stage Alzheimer's

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagn...

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are formed in a brain without exercise."
Preliminary research is showing much the same in humans; that staying physically fit may slow brain shrinkage.
Aerobic exercise, walking or anything that gets the heart pumping increases blood volume and promotes new cell growth. It's that cell growth that's linked to improved memory.
"So if you want to stay at home longer then physical exercise slows the memory loss by generating new nerve cells making the cells that are there healthier," says Dr. Raab.
And it's not just the body that could use a workout.
"By adding the brain exercises, especially the processing speed and reasoning, and retraining yourself and how to use your brain more efficiently through the memory techniques you're able to slow down the impact on your function and your ability to do things in life," says Dr. Raab.
It's well known that staying fit helps older adults without dementia offset cognitive decline. The hope is that Alzheimer's sufferers can put physical activity to work for them too.
View More HealthMatters video segments at leememorial.org/healthmatters/
Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries.
Visit leememorial.org/caring

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are formed in a brain without exercise."
Preliminary research is showing much the same in humans; that staying physically fit may slow brain shrinkage.
Aerobic exercise, walking or anything that gets the heart pumping increases blood volume and promotes new cell growth. It's that cell growth that's linked to improved memory.
"So if you want to stay at home longer then physical exercise slows the memory loss by generating new nerve cells making the cells that are there healthier," says Dr. Raab.
And it's not just the body that could use a workout.
"By adding the brain exercises, especially the processing speed and reasoning, and retraining yourself and how to use your brain more efficiently through the memory techniques you're able to slow down the impact on your function and your ability to do things in life," says Dr. Raab.
It's well known that staying fit helps older adults without dementia offset cognitive decline. The hope is that Alzheimer's sufferers can put physical activity to work for them too.
View More HealthMatters video segments at leememorial.org/healthmatters/
Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries.
Visit leememorial.org/caring

New Alzheimer's Research

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic fo...

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

Dr. Ronald Petersen discusses Alzheimer's research

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease...

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease had failed to show significant benefit to patients.
The trial used Eli Lilly’s drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of those with Alzheimer’s. The destruction of these plaques, which are a key player in the disease, had the potential to provide stabilization for Alzheimer’s patients. This goal, however, was not reached in the phase III clinical trial.

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease had failed to show significant benefit to patients.
The trial used Eli Lilly’s drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of those with Alzheimer’s. The destruction of these plaques, which are a key player in the disease, had the potential to provide stabilization for Alzheimer’s patients. This goal, however, was not reached in the phase III clinical trial.

Alzheimer's disease drug fails in trial

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually n...

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually no chance of finding a positive clinical effect.” The trial, called the EPOCH study, tested the efficacy and safety of the drug when taken orally in people with mild-to-moderate Alzheimer's disease. While this particular study was stopped, the president of Merck Research Laboratories, Dr. Roger M. Perlmutter, says in a news release that they will continue to study the drug in people with less advanced disease.
Mayo Clinic neurologist Dr. David Knopman says that while the news about this medication is disappointing, he remains optimistic about Alzheimer's Disease research. "We have to keep working towards therapies that are effective. As we become more knowledgeable about the disease, I think we will eventually achieve success."
Verubecestat is a base-inhibitor that breaks down a certain protein. The process then helps prevent the overproduction of amyloid protein, which many believe to be involved in causing Alzheimer's disease.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually no chance of finding a positive clinical effect.” The trial, called the EPOCH study, tested the efficacy and safety of the drug when taken orally in people with mild-to-moderate Alzheimer's disease. While this particular study was stopped, the president of Merck Research Laboratories, Dr. Roger M. Perlmutter, says in a news release that they will continue to study the drug in people with less advanced disease.
Mayo Clinic neurologist Dr. David Knopman says that while the news about this medication is disappointing, he remains optimistic about Alzheimer's Disease research. "We have to keep working towards therapies that are effective. As we become more knowledgeable about the disease, I think we will eventually achieve success."
Verubecestat is a base-inhibitor that breaks down a certain protein. The process then helps prevent the overproduction of amyloid protein, which many believe to be involved in causing Alzheimer's disease.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

Redefining Alzheimer's Disease: Mayo Clinic Radio

On the Mayo ClinicRadio podcast, Dr. CliffordJack Jr., a radiologist at Mayo Clinic, explains the importance of a new Alzheimer's disease framework for improving research and clinical trials. This interview originally aired May 26, 2018.

Alzheimer's disease drug shows early promise

One in 10 Americans over age 65 is living with Alzheimer’s disease.
There is no cure for Alzheimer’s disease, only medications to help treat the symptoms. And now, news about a drug that may slow the progression of the disease.
More health and medical news on the Mayo Clinic NewsNetwork. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/

Women’s Wellness: Hormone therapy and Alzheimer’s disease

There is research pointing to a reduced Alzheimer's risk in women who are given estrogen early in menopause because the hormone seems to slow down the accumulation of amyloid.
A drop in hormones during midlife may have some influence on a woman's chance of dementia or Alzheimer's. Volume of the brain gradually declines with advancing age, but the decline is faster in people who experience more cognitive decline. "Preserving brain volume during middle age, particularly in women as they transition into menopause, may protect against dementia and delay the occurrence of symptoms," says Dr. Kantarci, a radiologist in the Division of Neuroradiology at Mayo Clinic and does research in aging and dementia with imaging tools. She studies how the brain changes with aging and how brain diseases affect those changes, which can lead to dementia. She says imaging can provide a window into brain changes, decades before someone begins to show clinical symptoms of Alzheimer's or dementia.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

TDP43 and Alzheimer's Study

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease. Learn more: http://mayocl.in/2ieXXr5
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

Using Biomarkers to Predict and Prevent Alzheimer's Disease

Yakeel T. Quiroz, PhD, is the director of the FamilialDementia Neuroimaging Laboratory at Massachusetts General Hospital. For the past several years, she has been studying a Columbian family with autosomal dominant Alzheimer's disease. In this video, she discusses her research to find biomarkers that signal early brain changes associated with developing Alzheimer's Disease.
Read more here: https://advances.massgeneral.org/neuro/video.aspx?id=1066
Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
Subscribe: https://pages.connect.massgeneral.org/subscription-center-med-prof.html

Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report.
Using evidence from postmortem brain tissue from the Mount Sinai BrainBank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough.

Exercise in Early Stage Alzheimer's

The day her husband and lifelong partner Aldo was diagnosed is a day Dolores Bertolini will never forget.
"After three months of testing, and we got the diagnosis had had very early Alzheimer's disease."
It's not something that goes down easy.
"With his personality decided that was not a good diagnosis it was not a diagnosis for him and he was not gonna even address it and it would go away," says Dolores.
But experts advise being pro-active. One way to stay independent longer is to keep the body active. Animal testing shows a connection between exercise and the brain. Dr. Michael Raab works with the aging brain.
"The animal studies where animals exercise show that the number of new nerve cells formed in the brain when there's regular exercise is four times the number that are formed in a brain without exercise."
Preliminary research is showing much the same in humans; that staying physically fit may slow brain shrinkage.
Aerobic exercise, walking or anything that gets the heart pumping increases blood volume and promotes new cell growth. It's that cell growth that's linked to improved memory.
"So if you want to stay at home longer then physical exercise slows the memory loss by generating new nerve cells making the cells that are there healthier," says Dr. Raab.
And it's not just the body that could use a workout.
"By adding the brain exercises, especially the processing speed and reasoning, and retraining yourself and how to use your brain more efficiently through the memory techniques you're able to slow down the impact on your function and your ability to do things in life," says Dr. Raab.
It's well known that staying fit helps older adults without dementia offset cognitive decline. The hope is that Alzheimer's sufferers can put physical activity to work for them too.
View More HealthMatters video segments at leememorial.org/healthmatters/
Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries.
Visit leememorial.org/caring

New Alzheimer's Research

How many times have you lost your car keys? Or forgotten someone's name? We all have memory loss. It's a normal part of aging. But researchers at Mayo Clinic found that if you carry a gene known to increase the risk of Alzheimer's disease, your memory may decline faster than people without the gene, even if you never develop full blown Alzheimer's.

Dr. Ronald Petersen discusses Alzheimer's research

Many were disappointed recently when a major pharmaceutical company announced its clinical drug trial attempting to slow the advancement of Alzheimer’s disease had failed to show significant benefit to patients.
The trial used Eli Lilly’s drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of those with Alzheimer’s. The destruction of these plaques, which are a key player in the disease, had the potential to provide stabilization for Alzheimer’s patients. This goal, however, was not reached in the phase III clinical trial.

Alzheimer's disease drug fails in trial

The drug company Merck has announced it is halting a trial testing the Alzheimer's disease medication, verubecestat, after determining the drug has “virtually no chance of finding a positive clinical effect.” The trial, called the EPOCH study, tested the efficacy and safety of the drug when taken orally in people with mild-to-moderate Alzheimer's disease. While this particular study was stopped, the president of Merck Research Laboratories, Dr. Roger M. Perlmutter, says in a news release that they will continue to study the drug in people with less advanced disease.
Mayo Clinic neurologist Dr. David Knopman says that while the news about this medication is disappointing, he remains optimistic about Alzheimer's Disease research. "We have to keep working towards therapies that are effective. As we become more knowledgeable about the disease, I think we will eventually achieve success."
Verubecestat is a base-inhibitor that breaks down a certain protein. The process then helps prevent the overproduction of amyloid protein, which many believe to be involved in causing Alzheimer's disease.
More health and medical news on the Mayo Clinic NewsNetworkhttp://newsnetwork.mayoclinic.org/

Mayo Clinic

Mayo Clinic is a nonprofit medical practice and medical research group based in Rochester, Minnesota. It is the first and largest integrated nonprofit medical group practice in the world, employing more than 3,800 physicians and scientists and 50,900 allied health staff. The practice specializes in treating difficult cases through tertiary care. It spends over $500 million a year on research.

Dr. William Worrall Mayo settled his family in Rochester in 1864 and opened a medical practice that evolved under his sons into Mayo Clinic. Mayo Clinic is widely regarded as one of the world's greatest hospitals and ranked No. 1 on the 2014–2015 U.S. News & World Report List of "Best Hospitals", maintaining a position near the top for more than 20 years. It has been on the list of America's "100 Best Companies to Work For" published by Fortune magazine for eight consecutive years. It continued to achieve this ranking through 2015.

In addition to their flagship hospital in Rochester, the Mayo Clinic has major campuses in Arizona and Florida. The Mayo Clinic Health System also operates affiliated facilities throughout Minnesota, Wisconsin, and Iowa.

Pharmaceutical giant Biogen recently pulled the plug on its experimental Alzheimer’s drug after disappointing clinical trial results ... The disappointing announcement underscored how risky drug development is, especially for Alzheimer’s treatments ... As a result, it would hamstring research for breakthrough medicines....

Many health conditions and behaviors affect the odds of developing it, and research suggests that a third of cases are preventable, said Maria Carrillo, chief science officer of the Alzheimer’s Association, which has published similar advice ....

Dr. Ronald Petersen discusses Alzheimer's research...

Alzheimer's disease drug fails in trial...

Latest News for: alzheimer research

Pharmaceutical giant Biogen recently pulled the plug on its experimental Alzheimer’s drug after disappointing clinical trial results ... The disappointing announcement underscored how risky drug development is, especially for Alzheimer’s treatments ... As a result, it would hamstring research for breakthrough medicines....

Many health conditions and behaviors affect the odds of developing it, and research suggests that a third of cases are preventable, said Maria Carrillo, chief science officer of the Alzheimer’s Association, which has published similar advice ....

A 2001 study from researchers at Case Western Reserve University found that patients with Alzheimer’s disease were less active in early and middle adulthood in regard to intellectual, passive and physical activities than people who did not have AD....

The Alzheimer’s Association will hold ... Attendees will learn about the impact of Alzheimer's; the difference between Alzheimer's and dementia; stages and risk factors; current research and treatments available for some symptoms; and Alzheimer's Association resources....

At some point in your life, you’ll probably encounter friends or family living with Alzheimer’s disease ... I am an Alzheimer’s researcher ... If you are over age 50 and interested in monitoring your memory and advancing Alzheimer’s disease research, learn more at APTWebstudy.org ... Alzheimer’s Therapeutic ResearchInstitute....

Alzheimer’s is the best known of the dementias, the dementia that gets the most funding and research, the brain disease that affects one in three persons in the United States... When Karen reads about the hopeful advances in Alzheimer’s research, it always includes experiments on mice....

... and helping prevent and/or treat high blood pressure,2 heart disease, Alzheimer’s3 and even autism.4,5,6 Now, researchers report sulforaphane may also be helpful in the treatment of schizophrenia.7,8,9 Sulforaphane May Improve Cognition in Patients With Schizophrenia....

As they build up in your body, studies suggest, they promote aging and the conditions that come with it like osteoporosis and Alzheimer's disease. Researchers are studying drugs that can kill zombie cells and possibly treat the problems they bring ... The research has been done chiefly in mice ... In any case, experts are impressed by the research so far....